The U.S. Department of Justice alleged that Teva violated the Anti-Kickback Statute and the False Claims Act. The payment is in addition to the criminal penalty paid by Teva USA under its deferred ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the ...

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...

In the third episode of our mini series on artificial intelligence, Lori and guests continue their exploratory discussion on ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

Carlos Doti has moved countries and changed jobs, but one thing hasn’t changed. Making an impact on patient care has always ...

Seven children treated with bluebird bio ’s gene therapy Skysona for cerebral adrenoleukodystrophy, a rare and progressive neurodegenerative disease, developed blood cancers, according to a study ...

In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational ...